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Lipids play an important part as risk or protective factors for Alzheimer's disease. This review summarizes the current findings in which lipids
influence Alzheimer's disease and introduces the molecular mechanism how these lipids are linked to amyloid production. Besides the
pathological impact of amyloid in Alzheimer's disease, amyloid has a physiological function in regulating lipid homeostasis in return. The
understanding of the resulting regulatory cycles between amyloid precursor protein processing and lipids provides a platform for the development
of new causal therapeutic approaches for Alzheimer's disease.
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Alzheimer's disease (AD) is one of the most common forms
of dementia, affecting up to 15 million people world wide.
Above 60 years prevalence doubles every 5 years. 1% of⁎ Corresponding author. Tel.: +49 6841 1624130; fax: +49 6841 1647801.
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doi:10.1016/j.bbamem.2007.02.014individuals of 60–64 years suffer from AD. A percentage that
increases up to 40% of those who get older than 85 years. In an
aging population in which both, life expectancy and the average
age is increased, the ethical and the economical relevance is
going to increase even more [1,2].
The main characteristics of AD are massive cerebral
accumulation of amyloid composed of fibrillary aggregates of
the amyloid beta peptide (Aβ) and intracellular accumulation of
abnormally phosphorylated Tau protein leading to widespread
1992 E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001neurodegeneration. The clinical picture is characterized by
progressive and irreversible dementia, which is eventually fatal
(for reviews see [3–6]).
2. APP processing
Aβ is a proteolytic fragment of the larger amyloid precursor
protein (APP). The processing of APP is summarized in Fig. 1.
APP can be cleaved by two different ways. α-secretase
initiates the non amyloidogenic pathway and results in the
cleavage of APP within the Aβ domain, thus precluding the
generation of Aβ. Cleavage of APP by α-secretase yields α-
secreted APP (sAPPα) and the remaining membrane-bound C-Fig. 1. Non-amyloidogenic and amyloidogenic processing of APP by α-, β- and γ
secreted APP (sAPPα), β-secreted APP (sAPPβ), α-CTF, β-CTF, p3 and Aβ. Cleaterminal fragment α-CTF. Alternatively, the BACE-catalyzed
β-cleavage of APP initiates Aβ generation and the amyloido-
genic pathway. BACE cleavage results in β-secreted APP
(sAPPβ) and the C-terminal fragment β-CTF of APP. Both
membrane-bound C-terminal fragments of APP, α-CTF and β-
CTF, are substrates for γ-secretase, a ubiquitous multimeric
protease. The γ-secretase cleavage of α-CTF results in the
generation of a truncated non-amyloidogenic peptide (p3),
whereas γ-secretase cleavage of β-CTF leads to the generation
of Aβ, the main proteinaceous component of the amyloid
plaques found in brains of patients with AD. As β-CTF can be
cleaved at different sides by γ-secretase, Aβ varies in length;
mainly a 40 amino acid (aa) long peptide Aβ40 and a peptide-secretases. Schematic representation of APP and its proteolytic fragments α-
vage sites of α-, β- and γ-secretases are shown.
1993E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001which is 2 aa longer, Aβ42, are produced. Because of its
increased hydrophobicity Aβ42 is able to build aggregates and
is the predominant species of Aβ in senile plaques [7]. Both in
amyloidogenic and non-amyloidogenic pathway γ-secretase
cleavage results in the production of the APP intracellular
domain (AICD), which is reported to activate gene transcription
in the nucleus [8].
In addition, studies on the infrequent familial forms of
Alzheimer's disease (FAD) indicate increased production of
Aβ42 to be invariably associated with FAD and to cause AD
[3,4,9–11]. Moreover, age of disease onset correlates directly
with the Aβ40/42 ratio [12].
3. γ-secretase and regulated intramembrane proteolysis
γ-secretase is a multienzyme complex consisting up of at
least the proteins presenilin 1 (PS1), presenilin 2 (PS2), APH1,
PEN2 and Nicastrin [13].
The knock-out of both presenilins, PS1 and PS2, or the
mutation of the aspartatic residues D257 and D385 result in
complete loss of γ-secretase activity and Aβ production
[14,15], identifying the presenilins as active centre of the
γ-secretase complex.
Importantly, the γ-cleavage site of β-CTF is located in the
centre of the transmembrane domain of APP/β-CTF, possibly
causing sensitivity to alterations in membrane composition [16].
Such proteolytic events of regulated intramembrane proteolysis
(RIP) are involved in a number of cellular regulatory events
including lipid homeostasis [17–23].
4. Cholesterol and brain
The brain is one of the most cholesterol-rich organs.
Cholesterol is an essential factor of cell membranes and plays
a crucial role in the development and maintenance of neuronal
plasticity and function [24]. The homeostasis of cholesterol
including synthesis, removal, storage or transport in brain is
strictly regulated. One of the key enzymes in the biosynthetic
pathway of cholesterol (see Fig. 2) is the 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR) which catalyzes the
formation of mevalonate [25]. As this enzyme catalyzes the rate
limiting and committed step of the cholesterol biosynthesis,
HMGR is both a target for the physiological regulation of the
cholesterol homeostasis and for pharmacological inhibitors (e.g.
statins) [26].
In mature neurons endogenous cholesterol synthesis is
reduced and surplus cholesterol required for synaptic plasticity
is believed to be supplied by glial cells, primarily astrocytes
[27]. Most cholesterol used in the brain is synthesized in the
CNS and transport of cholesterol from peripheral circulation to
brain is prevented by an intact blood–brain barrier (only the
oxidized cholesterol products 27-hydroxycholesterol and 24S-
hydroxycholesterol [28] can pass the blood–brain barrier). The
exchange rate between peripheral and brain cholesterol is
approximately 1% per day. Therefore it has to be assumed that
cholesterol homeostasis of the brain is not completely
independent of blood cholesterol level [29].5. Cholesterol and APP
Until recently little indication existed, suggesting a link
between AD, APP processing and cholesterol homeostasis.
However, this picture changed dramatically over the last years
[30–33]. First indications that lipids may play an important role
in APP processing and Aβ production are given by the fact that
all proteins involved in processing are integral membrane
proteins. Taking into consideration that the Aβ generating
cleavage by the γ-secretase takes place in the middle of the
membrane, it is reasonable to assume that the lipid environment
of the cleavage enzymes influences Aβ production and hence
AD pathogenesis [16].
Cellular and biochemical studies indeed show that APP
processing and the proteases involved are sensitive to
cholesterol and cholesterol trafficking [34–42]. In vitro
enhanced cholesterol levels lead to increased Aβ production
[34]. Controversially, one report found a correlation between
mildly decreased cholesterol levels and increased Aβ produc-
tion in Chinese hamster ovary (CHO) cells [43]. In vivo studies
revealed that cholesterol feeding increases Aβ42 production
and amyloid burden whereas lowering cholesterol by medica-
tion (e.g. statins) decreases Aβ production and amyloid burden
[37,44–46].
Likewise, the relevance of cholesterol homeostasis in AD
was further substantiated in epidemiological studies [47,48].
There is an interesting link to the predominant AD risk gene
apolipoprotein E (ApoE) and AD [49,50], because this may
involve its function as a lipid transporting protein. However, the
molecular mechanism by which the disease linked allele ε4 of
ApoE causes earlier disease onset remains currently unresolved.
Moreover, an early increase in brain cholesterol levels during
disease progression [51] and studies on lipid composition in AD
brains [52] further support the importance of cholesterol and
lipids in AD.
Accordingly statin treatment is associated with a reduced AD
risk in some epidemiological studies [53–55]. The first
preliminary clinical trial came out with mixed results. High
statin dosage reduced cerebral Aβ levels and disease progres-
sion in mild AD [56]. When treatment duration was doubled
beneficial effects were observed in mild and moderate AD [57].
However, low statin dosage treatment for up to 12 months did
not show some potential secretase inhibition and clinical
benefits [58,59].
Important molecular evidence includes that cholesterol
enhance γ-secretase mediated Aβ production in vitro
[34,36,37,41,60], whereas inhibition of HMGR reduces Aβ
levels in cerebrospinal fluid and brain tissue [37]. Inhibition of
7-dehydro-cholesterol-reductase, which catalyzes the final step
of cholesterol biosynthesis, decreases amyloid load [46] and
cholesteryl-esters stimulate non-amyloidogenic APP degrada-
tion [61]. The Aβ generating machinery is highly responsive to
small alterations in lipid or cholesterol composition [34,36,
37,41] and even small changes that are induced by altering the
standard mouse diet to a cholesterol enriched diet causes
increased cerebral amyloid load [44,45]. Moreover, Aβ binds
cholesterol [62].
Fig. 2. Biochemical pathway of the de novo biosynthesis of cholesterol. The first committed step reaction in the formation of cholesterol occurs on the membranes of
the endoplasmatic reticulum by the HMG-CoA-reductase (all major enzymes are shown in blue). This rate-limiting reaction can be inhibited by statins (shown in red).
1994 E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001While dietary approaches and inhibition of cholesterol
synthesis by BM15.766 revealed that cholesterol modulates
Aβ levels in animals, the situation is apparently more complex
for the statin effect in mouse brains. In some studies statins
reduce Aβ, while some other studies find no effect on Aβ
production. In addition one study reported even an increased
Aβ production in female, but not in male mice. In mouse brains
statins did not show the expected change in cholesterol
metabolism or Aβ production, but an anti-inflammatory effect,
sometimes combined with improved cognitive performance
[63–67]. Some data indicate that this may be related to the way
how statins effect cholesterol metabolism in mouse brains.
Lutjohann [68] reported that in contrast to the lipophobic
pravastatin the lipophilic simvastatin reduced brain cholesterol
and increased HMGR expression. Both statins seem to change
cholesterol metabolism in guinea pigs [68,69]. A possibleexplanation for this is that guinea pigs might be more closely
related to the human brain lipid physiology. This is unfortunate,
because transgenic mice otherwise represent a most valuable
tool to study Alzheimer's disease in animal models [70–73].
Another conclusion from the difficulties with statins in mice is
of course that effects on Aβ production were only observed
when it coincided with a parallel change in cholesterol
metabolism. As much as this and the other studies point out
that cholesterol is critically involved in Aβ generation little is
known about the mechanism by which cholesterol affects APP
processing.
6. Gangliosides and APP
Gangliosides are glycosphingolipids, which are mainly
found in the outer leaflet of mammalian plasma membranes
1995E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001and are enriched in membranes of nervous system. GM1,
GD1a, GT1b and GD1b are the group of major gangliosides
found in brain [74]. It has been shown that an increased
sialidase activity, resulting in an increase of GM1, is found in
brains of AD patients [75,76]. Further studies revealed a
changed ganglioside pattern in AD brain emphasizing the
importance of glycosphingolipids for AD [77]. GM1 has been
detected in amyloid plaques bound to Aβ [78]. As a model it
was suggested that GM1-bound Aβ complexes can serve as a
seed for toxic amyloid fibril formation leading to neuronal
death. Moreover, an effect of GM1 on Aβ production was
observed [79]. Whereas γ-secretase activity seemed to be
increased by incubation of GM1 the non-amyloidogenic α-
secretase was reported to be decreased in the presence of GM1
[79]. Mechanistically it seems to be possible that GM1
decreases sAPPα secretion by inhibition of protein kinase C
(PKC), which positively regulates α-cleavage [80]. Another
explanation was given by the stiffening effect of GM1 on
membranes. In this model the inhibited lateral movement and
the reduced required contact between substrate and enzyme is
pointed out.
In vitro experiments indicated that in addition glyco-
sphingolipids are involved in the transport of APP in the
secretory pathway and its expression on the cell surface and
thereby altering the proteolytic processing of APP [81].
Apparently cholesterol is the most obvious but by far not the
only lipid with relevance to AD.
7. Lipid-rafts and AD
As summarized above both cholesterol and gangliosides,
especially GM1, drastically increases Aβ production. One of
the common characteristics between gangliosides and choles-
terol is that these lipids are major components of rafts.
Rafts are a concept of lipid microdomains that introduce
lateral heterogeneity into the membrane layer. It is assumed
that they represent ordered platforms that float in the liquid-
disordered matrix of the cellular membrane and form devices
to compartmentalize membrane processes. Biochemically
rafts can be characterized by their insolubility in detergents
(e.g. Triton X-100 or CHAPS) at 4 °C [82,83]. These deter-
gent resistant membranes (DRM) are involved in modulating
cellular function and cellular structures [84–87] including
APP processing [60,88–93]. BACE I and γ-secretase or PS
respectively are also present in rafts [88,89,91–94]. On the
other hand it could be shown that ADAM 10, which is a
putative α-secretase, was soluble after detergent extraction
[95]. These findings could be explained by a hypothetical
model that APP might be present in two different pools in
the membrane. The first pool is associated with rafts, where
the amyloidogenic pathway could take place and Aβ is
produced. The second APP pool in this model is localized
outside the DRM, where α-cleavage takes place. The
advantage of this model is that it could explain how the
same protein could be processed in two exclusive ways by
separating substrate and the different enzymes in different
membrane microdomains.8. Sphingolipids and APP processing
Besides cholesterol and gangliosides, sphingolipids, in
particular sphingomyelin (SM), play an important role in raft
biology [96].
Sphingolipids are generated by the condensation of palmi-
toyl-coenzymA and L-serine (by serine-palmitoyl-transferase
(SPT)) resulting in 3-dehydrosphinganine, which is metabolized
via several enzymes to ceramide (Cer) (see Fig. 3). Cer is one of
the most important branching point of this metabolic pathway.
Glycosylation of Cer leads to the glycosphingolipids, the
ceramidase catalyzes the reaction yielding in sphingosin and
the sphingomyelin-synthase metabolizes Cer to sphingomyelin
[97].
Elimination or inhibition of the entire sphingolipid biosynth-
esis at the level of the SPT has drastic effects on APP processing.
In CHO-cells α-secretase cleavage increases with the concomi-
tant accumulation of secretory APP. At the same time ε-cleavage
decreases while Aβ42 levels increase. Aβ40 levels and β-
cleavage remains unaltered [98]. It is currently difficult to judge
which molecular mechanism are responsible for those effects. A
possible explanation might be that SPT absence results in
multiple cellular changes, including absence of ceramide,
ganglioside and sphingosin production. As mentioned above,
the elimination of gangliosides alone is sufficient to distort APP
trafficking and hence APP processing. Interestingly, the APP
processing phenotype could be partly restored in SPT activity
deficient cells by inhibiting MAPK kinase, suggesting an
involvement of the MAPK/ERK pathway [98].
As expected cellular responses differ when instead of the
sphingolipid pathway specific lipids are targeted and analyzed
for their effect on APP processing. In contrast to cholesterol
and gangliosides, SM decreases Aβ production by inhibition
of the γ-secretase [99]. This surprising result was confirmed
by sphingomyelinase (SMase) inhibition experiments. SMases
are enzymes that break down SM to Cer. Inhibition of these
degrading enzymes lead to increased SM levels and decreased
Aβ-level. Interestingly, SMase activity is increased in PS-
FAD mutations, which may indicate a role of SMases in AD
[99]. The molecular mechanism how SM decrease γ-cleavage
of APP is unknown. One of many possibilities would be that
SM interacts with the γ-secretase complex lowering its
activity. Such a situation may exist for BACE I interaction.
SM and gangliosides increase BACE activity when present in
synthetic lipid vesicles, but activity is further increased when
replaced by cerebrosides, but it is unknown whether this
interaction is direct [100]. Locally, a given lipid may therefore
not work unilaterally, but rather its effect is determined by
concentration and composition of the lipid mixture with which
it forms the membrane domain analyzed.
This is also important in the context of a possible contra-
diction between these findings and the above described raft
model. Whereas cholesterol, gangliosides and SM are major
components of rafts, only SM decreases γ-secretase activity.
This difference might be based on the fact that sphingolipids, in
particular SM, lower plasma cholesterol [101], increased SM
production may therefore change raft properties unfavourably
Fig. 3. Sphingolipid biosynthesis. The biochemical pathway illustrates the sphingolipid biosynthesis beginning with the rate limiting enzyme serine-palmitoyl-CoA-
transferase (SPT). Starting from the branching point ceramide, sphingomyelin, glycosphingolipids and sphingosin can be synthesized. A crucial role in ceramide/SM
homeostasis plays the SM degrading enzyme SMase.
Fig. 4. Model of the feedback regulation between cholesterol homeostasis and
APP processing. Cholesterol increases γ-secretase activity, which leads to an
increased Aβ production. In return Aβ downregulates cholesterol de novo
synthesis leading to a regulatory cycle.
1996 E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001for γ-cleavage. Furthermore, SM has a strong tendency to bind
to cholesterol which might influence APP processing further.
In addition to SM there is a link of other sphingolipids to AD
as well. Sphingosin is considered to affect PKC [102] and
therefore influences α-secretase. Cer can modulate a variety of
cellular effects ranging from proliferation and differentiation to
growth arrest and apoptosis [103]. Cer induced apoptosis might
play an important role under pathological conditions such as in
AD [104]. On account of these examples an additional
mechanism of the described lipids is pointed out. Besides an
influence of lipids on APP processing by influencing the lipid
environment, bioactive (sphingo-)lipids serve as highly regu-
lated second messenger in cascades interfering with AD.
Although several aspects remain unclear, the aforementioned
and further augmenting evidence suggests, that the link between
lipids and AD aetiopathology is substantial and comprehensive.
However, missing in this scheme is a functional link that
elucidates the specific lipid sensitivity of this proteolytic system.
9. APP processing and cholesterol metabolism, a regulatory
feedback cycle
The above mentioned findings summarize that some lipid
classes are able to influence APP processing and therefore affectAβ-production and AD. First indications that not only lipids
influence APP processing but APP processing also influences
lipid metabolism were given by the fact that in absence of PS
membrane fluidity is decreased [105]. As cholesterol has a
condensing effect on membranes [106] and is an important
regulator of membrane fluidity, indications were given that
Fig. 5. Comparison of cholesterol regulation via SREBP/SCAP system and APP processing. In both systems cholesterol influences the regulated intramembrane
proteolysis (RIP). Whereas cholesterol inhibits S1P cleavage in the SREBP system APP processing by γ-secretase is enhanced by cholesterol. Similarly the proteolytic
cleavage products of this regulation results in decreased Aβ40 or increased SREBP S1P cleavage leading both to increased cholesterol synthesis. This results in a
regulatory cascade, which allows to adjust the cholesterol homeostasis.
1997E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001γ-secretase activity may alter cholesterol levels. Indeed in PS
deficient fibroblasts cholesterol levels are increased. These
results were reproduced in mice brain, where PS is conditionallyFig. 6. Model of the feed forward regulatory cycle between sphingolipids and APP
γ-secretase activity leads to an decreased nSMase activity and therefore an increased
regulation of Aβ42 on nSMase could be shown.knocked out, emphasizing the in vivo relevance of this finding.
Moreover, in vivo and in vitro, it could be shown that the
absence of the γ-secretase substrate APP results in virtually theprocessing. Sphingomyelin decreases γ-secretase activity and in return reduced
SM level. SMase and SM-synthase are regulated inversely. For SMase a direct
1998 E.G. Zinser et al. / Biochimica et Biophysica Acta 1768 (2007) 1991–2001same cholesterol increase. In addition PS-FAD mutations with
increased Aβ42 and decreased Aβ40 levels show an increased
cholesterol level, too [99]. This suggests that Aβ40 inhibits
cholesterol synthesis. In line with these results PS deficient cells
incubated with Aβ40 show decreased HMGR activity and
decreased cholesterol level. Taken together this suggests a
negative feed back cycle (see Fig. 4).
On one hand cholesterol increases γ-secretase activity and
Aβ-production, on the other hand Aβ, especially Aβ40,
decreases HMGR-activity and cholesterol synthesis. Whether
this regulation of the HMGR by Aβ40 is direct or mediated via
another metabolite is currently unclear. Because of the
localization of the HMGR in the membrane of the endoplas-
matic reticulum (ER) [107], both options seem to be possible,
but due to the low Aβ40 level in the ER [108], a signal
transmission via another metabolite might be preferred.
10. Analogies of the SREBP and APP lipid regulatory
systems
Following the discovery of the lipid-controlled RIP mechan-
ism of the sterol regulatory element binding protein (SREBP)
with site-1 protease (S1P) and site-2 protease (S2P), this
represents a second proteolytic system in lipid homeostasis (see
Fig. 5). Whereas high cholesterol inhibits S1P cleavage of
SREBP and therefore the transcription of the cholesterol
synthesizing enzyme HMGR [109], cholesterol increases
γ-secretase cleavage of APP, resulting in high Aβ levels,
which inactivate HMGR enzyme activity.
Although there are no sequence homologies, the functional
analogies to the system presented here are striking. Both
systems act via HMGR, but an important difference is that APP
processing reduces, whereas SREBP processing upregulates
cholesterol de novo synthesis. In a further analogy, the example
of S2P suggests that not all γ-secretase substrates are processed
lipid-dependently.
11. APP processing regulates sphingolipid homeostasis
A further regulatory cycle between APP processing and
sphingolipid homeostasis was observed. As summarized above,
in contrast to cholesterol sphingomyelin decreases γ-secretase
activity and Aβ-production. On the other hand both, PS or APP
deficiency, results in increased SM levels [99] (see Fig. 6).
It could be demonstrated that Aβ in particular Aβ42, directly
activates the neutral SMase (nSMase), the SM degrading
enzyme. In line with this finding PS-FAD mutations with an
increased Aβ42 ratio showed an increased nSMase activity and
therefore a corresponding decreased SM level. Again a
physiological function of Aβ is linked to pathological processes
in AD by this finding.
Whereas under physiological conditions an effect of Aβ to
the SMase via reactive oxidative species (ROS) could be
excluded, under pathological conditions with highly increased
Aβ levels ROS may play an active part in the activation of the
SMase [110]. Under these conditions an accumulation of the
degradation product of SM, the second messenger Cer could berelevant for neuronal survival as Cer can serve as an apoptotic
mediator [111].
Many questions remain unanswered by this short review. But
almost entirely neglected for more than 80 years of AD
research, lipid biology has become one of the most attractive
and fastest advancing fields in AD research. The hope is now
that this will lead to effective therapeutic and preventive
treatments for AD. There is reason to believe that this hope is
not entirely unsubstantiated. With several ongoing lipid
metabolism targeting clinical trials, major advances in the
understanding of the molecular mechanism and most recently
with the discovery of the physiological basis of Aβ generation
as essential part of a complex lipid homeostasis regulatory
cascade, the field appears at least to be on a promising track.
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